Efficacy of recombinant human endostatin on relapsed refractory multiple myeloma

Abstract

Objective To observe the clinical safety and efficacy of recombinant human endostatin (rhES) in patients with relapsed refractory multiple myeloma (RRMM). Methods The clinical data of 25 cases who accepted rhES combined with VD regimen, 22 cases who accepted Tha plus VD regimen, 32 cases who accepted rhES combined with routine regimen and 32 cases who received Tha plus routine regimen were analyzed retrospectively. The overall response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events of the four groups were observed. Results ORRs between rhES combined with VD group (76 %, 19/25) and Tha combined with VD group (59 %, 13/22) and between rhES combined with routine regimen group (44 %, 14/32) and Tha combined with routine regimen group (34 %, 11/32) were no statistical differences (χ2= 1.540, P= 0.215; χ2= 0.591, P = 0.442). The median follow-up time was 7.5 months (0.4 -27.6 months) with 21 cases died, 3 case lost to follow-up. The median PFS and median OS in rhES combined with VD group were 6.9 months (0.5-17.3 months) and 15.7 months (0.5-27.6 months), and those in Tha combined with VD group were 5.2 months (0.5-14.6 months) and 13.4 months (0.5-24.9 months). The difference of PFS between both groups had statistical significance (P= 0.031), but the difference of OS had no (P= 0.129). The median PFS and median OS in rhES combined with routine regimen group were 5.1 months (0.6-11.7 months) and 6.3 months (0.6-18.6 months), and those in Tha combined with routine regimen were 2.7 months (0.4-8.0 months) and 3.4 months (0.4-15.7 months). The differences of PFS between both groups had statistical significance (P= 0.017), but the difference of OS had no (P= 0.123). The adverse effects of all patients mainly included infection caused by bone marrow depression and constipation, but there were no significant differences between the groups (P > 0.05). Conclusions rhES may be an effective supplement to the chemotherapy of RRMM, which will prolong the PFS and improve the life quality. Key words: Multiple myeloma; Endostatin; Relapsed; Refractory